TheraSphere Japan Pre-Market Study

To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.

Trial Details

NCT ID
NCT07377487
Phase
NA
Sponsor
Boston Scientific Corporation
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • TheraSphere Y-90 glass microsphere
Locations (sample)
  • Nishinomiya, Hyōgo, Japan|34.71562,135.33199
  • Kanazawa, Ishikawa-ken, Japan|36.6,136.61667
  • Sayama, Osaka, Japan|34.51685,135.56298
  • Chuo Ku, Tokyo, Japan

Key Eligibility Criteria

  • \[Inclusion criteria based on the clinical evaluation\]
  • Patient aged \>18 years at time of consent
  • Patient is able and willing to participate in the study and has provided written informed consent
  • Patient who is determined to have failed or not be eligible for standard treatment by the multidisciplinary board

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →